Plain-English translation of NCT04265872 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Breast Cancer research guide โPhase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This trial is testing whether bortezomib, given first, can prepare cancer cells to be more vulnerable to a two-drug combination of pembrolizumab and cisplatin. The study is designed for women whose advanced triple-negative breast cancer has already been treated with standard chemotherapy but has continued to grow or spread. Researchers hope that this three-step approach will help the immune system and chemotherapy work better together against this aggressive type of breast cancer.
Triple-negative breast cancer is particularly hard to treat because it doesn't respond to many common hormonal therapies. This trial is based on early evidence suggesting that the first medication might make cancer cells more responsive to the combination of the second and third medications, potentially offering patients with this challenging diagnosis a new treatment option when standard therapies have stopped working.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will first receive bortezomib as an injection until your cancer stops responding to it. Once that happens, you will then receive pembrolizumab and cisplatin together for up to 6 treatment cycles. Throughout the study, you will have regular blood tests and scans to monitor how you are responding. You will also have tissue biopsies (small samples of cancer) taken at the beginning of the study and when your cancer starts progressing, so researchers can understand how the medications are affecting your cancer at a molecular level.
AI-generated summary from trial data ยท Jun 30, 2026 ยท Not medical advice
United States